Omnicell (OMCL) Projected to Release Quarterly Earnings on Thursday

Key Points

• Omnicell is expected to report Q3 2026 results before the market opens on October 29, with analysts forecasting $0.4175 in earnings per share and $304.45 million in revenue. The company’s quarterly EPS guidance is $0.350–$0.430.
• In the prior quarter, Omnicell reported $0.94 EPS and $312.21 million in revenue, surpassing consensus estimates, while revenue increased 7.4% year over year.
• Analyst sentiment remains positive, with seven Buy ratings and two Hold ratings, producing a “Moderate Buy” consensus and an average price target of $57.86 versus the stock’s recent $36.34 price.

Omnicell (NASDAQ:OMCL - Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $0.4175 per share and revenue of $304.45 million for the quarter. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Interested persons may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.47. The company had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%. Omnicell's quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.45 earnings per share. On average, analysts expect Omnicell to post $1.41 EPS for the current fiscal year and $1.03 EPS for the next fiscal year.

Omnicell Stock Performance

Shares of OMCL opened at $36.34 on Thursday. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. The business has a 50-day simple moving average of $34.51 and a two-hundred day simple moving average of $38.57. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of 43.26, a PEG ratio of 0.92 and a beta of 0.98. Omnicell has a 52 week low of $29.09 and a 52 week high of $55.00.

Analysts Set New Price Targets

A number of research firms have recently weighed in on OMCL. Weiss Ratings raised Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, August 18th. Wells Fargo & Company reduced their target price on shares of Omnicell from $55.00 to $50.00 and set an "overweight" rating for the company in a report on Friday, July 31st. Piper Sandler reissued an "overweight" rating and issued a $45.00 target price (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. KeyCorp restated an "overweight" rating on shares of Omnicell in a research note on Monday, August 24th. Finally, Zacks Research raised shares of Omnicell from a "strong sell" rating to a "hold" rating in a report on Monday, September 7th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, Omnicell currently has an average rating of "Moderate Buy" and a consensus target price of $57.86.

About Omnicell

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company's product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.